Shandong Boan Biotechnology reported early antitumor activity for BA-1302, a CD228-targeted antibody-drug conjugate, in a Phase Ia trial in China. The initial dataset includes responses among heavily pretreated patients with advanced solid tumors. The company’s update adds to the growing set of CD228-targeting strategies in ADCs, where early activity, tolerability, and evidence of target engagement drive the next dose-expansion decisions. Boan framed the study as progressing clinical evaluation to refine dosing and patient selection. Key near-term milestones will include expansion cohorts by tumor type and clearer safety margins, especially given the typical toxicity profile and steep dose-response dynamics that can accompany ADCs.